REGENXBIO Inc. (RGNX) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome everyone to the second quarter of 2026 Regenexx BIO Earnings Conference Call. My name is Elaine and I will be your conference operator today. All lines have been placed on mute to prevent any background noise. And after the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star then one, number one on your telephone keyboard. To withdraw your question, press star 1 again. At this time, I'd like to turn the conference over to Patrick Christmas, Chief Legal Officer of Regenexx BIO. Please go ahead. Good morning, and thank you for joining us today. Earlier this morning, Regenexx BIO released financial and operating results for the second quarter ended June 30, 2026. The press release is available on our website at www.genxbio.com. Today's conference call will include forward-looking statements regarding our financial outlook in addition to regulatory and product development plans. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted and can be identified by words such as expect, plan, will, may, anticipate, believe, should, intend, and other words of similar meaning. Any such forward-looking statements are not guarantees of future performance and involve certain risks and uncertainties. These risks are described in the risk factors and the management's discussion and analysis sections of Regenexx BIO's annual report on Form 10-K for the full year ended December 31st, 2025, and comparable risk factor sections of Regenexx BIO's quarterly reports on Form 10-Q, which will be on file with the Securities and Exchange Commission available on the SEC's website. Any information we provide on this conference call...